Literature DB >> 14595813

Signal pathway profiling of prostate cancer using reverse phase protein arrays.

Robert L Grubb1, Valerie S Calvert, Julia D Wulkuhle, Cloud P Paweletz, W Marston Linehan, John L Phillips, Rodrigo Chuaqui, Alfredo Valasco, John Gillespie, Michael Emmert-Buck, Lance A Liotta, Emanuel F Petricoin.   

Abstract

Reverse phase protein arrays represent a new proteomics microarray technology with which to study the fluctuating state of the proteome in minute quantities of cells. The activation status of cell signaling pathways controls cellular fate and deregulation of these pathways underpins carcinogenesis. Changes in pathway activation that occur between early stage prostatic epithelial lesions, prostatic stroma and the extracellular matrix can be analyzed by obtaining pure populations of cell types by laser capture microdissection (LCM) and analyzing the relative states of several key phosphorylation points within the cellular circuitry. We have applied reverse phase protein array technology to analyze the status of key points in cell signaling involved in pro-survival, mitogenic, apoptotic and growth regulation pathways in the progression from normal prostate epithelium to invasive prostate cancer. Using multiplexed reverse phase protein arrays coupled with LCM, the states of signaling changes during disease progression from prostate cancer study sets were analyzed. Focused analysis of phospho-specific endpoints revealed changes in cellular signaling events through disease progression and between patients. We have used a new protein array technology to study specific molecular pathways believed to be important in cell survival and progression from normal epithelium to invasive carcinoma directly from human tissue specimens. With the advent of molecular targeted therapeutics, the identification, characterization and monitoring of the signaling events within actual human biopsies will be critical for patient-tailored therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595813     DOI: 10.1002/pmic.200300598

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  36 in total

Review 1.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

Review 2.  Validation and quality control of protein microarray-based analytical methods.

Authors:  Larry J Kricka; Stephen R Master
Journal:  Mol Biotechnol       Date:  2007-08-03       Impact factor: 2.695

3.  Variable slope normalization of reverse phase protein arrays.

Authors:  E Shannon Neeley; Steven M Kornblau; Kevin R Coombes; Keith A Baggerly
Journal:  Bioinformatics       Date:  2009-03-31       Impact factor: 6.937

Review 4.  Histo-proteomic profiling of formalin-fixed, paraffin-embedded tissue.

Authors:  Kant M Matsuda; Joon-Yong Chung; Stephen M Hewitt
Journal:  Expert Rev Proteomics       Date:  2010-04       Impact factor: 3.940

5.  Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.

Authors:  Amjad P Khan; Laila M Poisson; Vadiraja B Bhat; Damian Fermin; Rong Zhao; Shanker Kalyana-Sundaram; George Michailidis; Alexey I Nesvizhskii; Gilbert S Omenn; Arul M Chinnaiyan; Arun Sreekumar
Journal:  Mol Cell Proteomics       Date:  2009-11-09       Impact factor: 5.911

6.  Increasing the sensitivity of reverse phase protein arrays by antibody-mediated signal amplification.

Authors:  Jan C Brase; Heiko Mannsperger; Holger Fröhlich; Stephan Gade; Christian Schmidt; Stefan Wiemann; Tim Beissbarth; Thorsten Schlomm; Holger Sültmann; Ulrike Korf
Journal:  Proteome Sci       Date:  2010-06-22       Impact factor: 2.480

Review 7.  Histopathological markers of treatment response and recurrence risk in ovarian cancers and borderline tumors.

Authors:  S Avril
Journal:  Pathologe       Date:  2017-11       Impact factor: 1.011

8.  Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures.

Authors:  Robert L Grubb; Jianghong Deng; Peter A Pinto; James L Mohler; Arul Chinnaiyan; Mark Rubin; W Marston Linehan; Lance A Liotta; Emanuel F Petricoin; Julia D Wulfkuhle
Journal:  J Proteome Res       Date:  2009-06       Impact factor: 4.466

9.  Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer.

Authors:  Tobias Grote; Doris R Siwak; Herbert A Fritsche; Corwin Joy; Gordon B Mills; Diane Simeone; David C Whitcomb; Craig D Logsdon
Journal:  Proteomics       Date:  2008-08       Impact factor: 3.984

10.  RPPAML/RIMS: a metadata format and an information management system for reverse phase protein arrays.

Authors:  Romesh Stanislaus; Mark Carey; Helena F Deus; Kevin Coombes; Bryan T Hennessy; Gordon B Mills; Jonas S Almeida
Journal:  BMC Bioinformatics       Date:  2008-12-22       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.